8JM Stock Overview
A veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for 8JM from our risk checks.
Vetoquinol SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €80.20 |
| 52 Week High | €108.20 |
| 52 Week Low | €79.00 |
| Beta | 0.94 |
| 11 Month Change | -3.49% |
| 3 Month Change | -15.67% |
| 1 Year Change | -5.09% |
| 33 Year Change | -46.17% |
| 5 Year Change | n/a |
| Change since IPO | -25.05% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8JM | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -1.2% | -1.8% | -1.8% |
| 1Y | -5.1% | -12.8% | 13.6% |
Return vs Industry: 8JM exceeded the German Pharmaceuticals industry which returned -12.8% over the past year.
Return vs Market: 8JM underperformed the German Market which returned 13.6% over the past year.
Price Volatility
| 8JM volatility | |
|---|---|
| 8JM Average Weekly Movement | 4.3% |
| Pharmaceuticals Industry Average Movement | 7.9% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 8JM has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 8JM's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1933 | 2,519 | Matthieu Frechin | www.vetoquinol.com |
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France.
Vetoquinol SA Fundamentals Summary
| 8JM fundamental statistics | |
|---|---|
| Market cap | €939.50m |
| Earnings (TTM) | €47.14m |
| Revenue (TTM) | €537.47m |
19.9x
P/E Ratio1.7x
P/S RatioIs 8JM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8JM income statement (TTM) | |
|---|---|
| Revenue | €537.47m |
| Cost of Revenue | €250.03m |
| Gross Profit | €287.44m |
| Other Expenses | €240.30m |
| Earnings | €47.14m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.98 |
| Gross Margin | 53.48% |
| Net Profit Margin | 8.77% |
| Debt/Equity Ratio | 1.2% |
How did 8JM perform over the long term?
See historical performance and comparison